These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9723230)

  • 1. Variability of Sandimmune pharmacokinetics in renal transplant patients.
    Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
    Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
    [No Abstract]   [Full Text] [Related]  

  • 2. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
    Markell MS; Homel P; Sumrani N; Hong JH; Distant DA; Miles AM; Sommer BG; Friedman EA
    Transplant Proc; 1998 Aug; 30(5):1980-2. PubMed ID: 9723360
    [No Abstract]   [Full Text] [Related]  

  • 4. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 5. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 6. Neoral versus Sandimmune in kidney transplantation.
    Tisone G; Orlando G; Mercadante E; Vennarecci G; Pisani F; Buonomo O; Negrini S; Casciani CU
    Transplant Proc; 1998 Aug; 30(5):1749-50. PubMed ID: 9723265
    [No Abstract]   [Full Text] [Related]  

  • 7. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
    Chueh SC; Liao CH; Lai MK
    Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
    [No Abstract]   [Full Text] [Related]  

  • 8. Relationship between maintenance dose of cyclosporine and long-term kidney graft survival. Collaborative Transplant Study.
    Opelz G
    Transplant Proc; 1998 Aug; 30(5):1716-7. PubMed ID: 9723253
    [No Abstract]   [Full Text] [Related]  

  • 9. Time-dependent difference of the 12-hour trough levels of cyclosporine in renal transplant recipients with sandimmune capsule.
    To H; Haba T; Uchida K; Fujimura A; Kobayashi E
    Transplant Proc; 2000 Feb; 32(1):221-2. PubMed ID: 10701028
    [No Abstract]   [Full Text] [Related]  

  • 10. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
    Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
    Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
    [No Abstract]   [Full Text] [Related]  

  • 11. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
    Crocker J; Renton K; Wade A; McLellan H; Acott P
    Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
    [No Abstract]   [Full Text] [Related]  

  • 12. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
    Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
    Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal recipients of haploidentical living donors treated with Neoral or conventional cyclosporine: a comparative follow-up of 3 years.
    Gracida C; Melchor JL
    Transplant Proc; 1998 Aug; 30(5):1742-3. PubMed ID: 9723262
    [No Abstract]   [Full Text] [Related]  

  • 14. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
    Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
    Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
    Suh BY; Kwun OS; Kwun KB
    Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
    [No Abstract]   [Full Text] [Related]  

  • 16. Trough cyclosporine concentration variability.
    Savoldi S; Maiorca R; Chiappini R; Scolari F; Sandrini S
    Transplant Proc; 1998 Aug; 30(5):1642-4. PubMed ID: 9723225
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
    Gaspari F; Anedda MF; Signorini O; Amuchastegui SC; Perico N; Remuzzi G
    Transplant Proc; 1998 Aug; 30(5):1654-5. PubMed ID: 9723229
    [No Abstract]   [Full Text] [Related]  

  • 19. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant.
    Rial MC; Frias S; Argento J; Tessler J; Casadei D
    Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduced variability of neoral pharmacokinetic studies in pediatric renal transplantation.
    Meier-Kriesche HU; Swinford R; Kahan BD; Brannan P; Portman RJ
    Pediatr Nephrol; 2000 Nov; 15(1-2):2-6. PubMed ID: 11095000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.